Restructuring Corporate Fertility Coverage: The $120,000 Limited Excepted Benefits Exemption

By officially classifying these benefits outside of traditional primary health plans, the administration is deliberately allowing employers to sidestep the Affordable Care Act's bans on coverage limits and its mandatory protections, such as essential health benefits and annual out-of-pocket maximums. This solves a critical corporate hesitation. Employers can now offer high-dollar fertility perks without exposing their general assets to the infinite financial liability of uncapped, endless fertilization cycles. The architecture of this proposed rule relies on the statutory authority granted to these departments to define additional categories of limited excepted benefits that operate similarly to limited-scope dental or vision plans. The groundwork for this structure was laid in October 2025, when the Department of Labor issued a roadmap signaling that employers could soon offer standalone fertility insurance completely severed from their primary medical plans. A primary mechanism of this regulatory restructuring is the imposition of a strict lifetime financial ceiling on the exempted coverage. The total lifetime benefit per participant, alongside any eligible beneficiaries, is statutorily capped at $120,000. This specific monetary threshold was calibrated against the prevailing costs of in vitro fertilization, which averages between $15,000 and $20,000 per single cycle and often exceeds $40,000 when multiple cycles are required to achieve a successful pregnancy. The lifetime dollar limit is not static. For plan years commencing after December 31, 2027, the $120,000 threshold will be mathematically indexed to medical inflation. The adjustment is calculated using the overall medical care component of the unadjusted Consumer Price Index for All Urban Consumers published by the Department of Labor. The coverage must be strictly confined in scope to benefits substantially dedicated to the diagnosis, mitigation, or treatment of infertility or infertility-related reproductive health conditions. The items and services must be delivered by medical professionals authorized to practice under applicable state or federal law. The scope explicitly accommodates treatments addressing underlying reproductive health conditions causing infertility, including endometriosis, uterine fibroids, male hypogonadism, and environmental endocrine disruptors. The regulatory text permits coverage for standard diagnostic tools such as hysteroscopies, laparoscopies, semen analyses, and hormone panel blood tests. Coverage extends to advanced assisted reproductive technology procedures, including in vitro fertilization, gamete intrafallopian transfer, and zygote intra-fallopian transfer. This comprehensive definition directly complements "TrumpRx," the recently launched federal website designed to provide patients with direct, heavily discounted access to common fertility medications like Gonal-F, Ovidrel, and Cetrotide, cutting some pharmaceutical costs by up to 84 percent. The Departments deliberately avoided imposing procedural limitations, such as a cap on the number of authorized in vitro fertilization cycles, opting instead to let the $120,000 lifetime financial ceiling serve as the definitive limiting principle. To qualify for the market exemption, the fertility benefit must not function as an integral part of the primary group health plan. This separation can be achieved by providing the fertility benefits through an entirely separate policy, certificate, or contract of insurance. If the benefits are self-funded and not issued under a separate policy, the plan sponsor must maintain a traditional group health plan that is not limited to expected benefits. This separation of benefits creates a fragmented, two-tiered healthcare reality. A standalone fertility plan is ultimately of limited utility if the employee lacks comprehensive primary insurance to cover the high-cost prenatal and maternity care required for the resulting pregnancy. Only individuals eligible to participate in the traditional group health plan may be offered the expected fertility benefit. Participants are granted the legal right to enroll in the expected fertility benefit while simultaneously declining coverage under the sponsor's traditional group health plan. Sponsors are legally permitted to charge employee premiums, require contributions, and impose cost-sharing requirements for this standalone fertility coverage. Because these plans are not federally subsidized and there are no new tax incentives compelling employers to absorb the cost, it is highly likely that corporate sponsors will shift heavy premium burdens directly onto their employees, effectively neutralizing the financial relief the rule intends to provide. A mandatory compliance trap exists in the form of a strict notice requirement designed to function as an executive summary for eligible employees. Plan sponsors must distribute a written document outlining the summary of benefits, the network provider utilization protocols, the claims submission procedures, and a clear declaration of the $120,000 lifetime limit. This notice must explicitly state whether the fertility benefit utilizes the exact same claims procedure as the sponsor's primary medical plan. The disclosure must be written at or below an eighth-grade reading level, stripping away complex medical terminology and technical jargon to prevent participant confusion. Distribution of this notice must occur no later than the first date an employee becomes eligible to enroll in the coverage, with subsequent distributions required annually or upon explicit request. The rule targets an implementation timeline for group health plans and health insurance issuers offering group health insurance coverage for plan years beginning on or after January 1, 2027. The Department of Health and Human Services is actively considering mirroring this exact regulatory architecture for the individual market to allow standalone excepted fertility policies to be sold directly to consumers. The financial modeling underpinning this rule estimates that approximately 54.4 million participants and beneficiaries could be offered these new excepted fertility benefits. The data suggests that roughly 743,361 individuals in non-Federal employer-sponsored health plans aged twenty-five to forty-five would likely seek out and enroll in this coverage annually. The regulatory impact analysis projects that this carve-out will shift significant financial risk from individual employees directly to the self-insured plans and issuers offering the expected coverage. However, macroeconomists warn of severe downstream consequences, noting that flooding the private market with $120,000 corporate fertility allowances will completely evaporate consumer price sensitivity, incentivizing fertility clinics to dramatically raise their base rates for medical procedures across the board. A severability clause has been embedded into the text, ensuring that if any single provision, such as the notice requirement, is invalidated by federal courts, the remainder of the excepted benefit framework will survive and remain legally enforceable. Fully insured plans operating in the fifteen states that already mandate in vitro fertilization coverage are likely preempted from utilizing this expected benefit structure to bypass existing state-level insurance mandates. This sets the stage for a highly localized geographic divide. Employers in states without mandates will rapidly adopt these federally shielded carve-outs, while companies anchored in states with pre-existing fertility mandates will remain trapped under heavier, uncapped state regulations, potentially driving corporate headquarters to relocate to states with more favorable regulatory environments.